Company intelligence / Profile preview

Ollin Biosciences

Chicago, Illinois, United States

Ownership: Private
Development stage: Other

Overview

Ollin has acquired global (ex-China) rights to VBS-102, a first-in-class bispecific antibody targeting IGF-1R x TSHR for ophthalmic indications, currently in preclinical development with no disclosed human results; the company is funding academic research in glaucoma but has not announced internal clinical-stage data

Therapeutic areas: Ophthalmology
Modalities: Bispecific antibody
Industry: Biotech

Drug pipeline

2 assets

OLN324

1 more asset in the full pipeline.

Request access →

Partnerships

VelaVigo Cayman Limited (exclusive licensing of VBS-102, with milestone and royalty structure)

Beyond the preview

Go deeper on Ollin Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ollin Biosciences.

Explore the full profile